What Does the Brazil Cannabis Market 2026 Landscape Look Like for International Operators?
The Brazil cannabis market 2026 represents one of the most significant opportunities in global cannabis. With over 215 million people, Latin America’s largest country has crossed a regulatory threshold that investors, operators, and compliance professionals have anticipated for years. In January 2026, ANVISA (Agencia Nacional de Vigilancia Sanitaria) approved a sweeping new regulatory framework establishing clear rules for cannabis cultivation, manufacturing, and research for the first time in the country’s history. For international operators evaluating where to deploy capital and expertise, the Brazil cannabis market 2026 demands serious attention.
This guide breaks down the market size, ANVISA’s four new RDC resolutions, license types, entry requirements, and how cannabis compliance software can position your operation for success in this emerging powerhouse.
Key Takeaways
- 672,000+ registered patients: Brazil surpassed this milestone in 2024, a 56% year-over-year increase — demand is already proven.
- Four new ANVISA RDCs: Published February 2026, covering medicinal cultivation, research cultivation, regulatory sandbox, and sanitary standards — taking effect August 4, 2026.
- R$15 billion market by 2034: Brazil’s medicinal cannabis sector is projected to reach this milestone, requiring 64,000 hectares and creating 15,000 jobs.
- 0.3% THC cultivation limit: The new framework permits cultivation of Cannabis sativa L. with THC content at or below 0.3% for medicinal and research purposes.
- Compliance deadline August 5, 2027: Operators currently working under court decisions have until this date to achieve full ANVISA compliance.
Brazil Cannabis Market 2026: Size, Growth & Patient Data
Understanding the scale of the Brazil cannabis market 2026 begins with the numbers. Brazil is not an emerging market in the experimental sense — it is a massive healthcare economy where cannabis demand has already outpaced regulatory infrastructure for years.
Patient Growth and Market Revenue
Brazil surpassed 672,000 registered medical cannabis patients by the end of 2024, representing a 56% increase from the previous year. These patients are spread across more than 80% of Brazilian municipalities, demonstrating that demand is not confined to major urban centers like Sao Paulo or Rio de Janeiro.
In 2024, the sector generated R$853 million (approximately USD 170 million) in revenue, with product sales increasing by 65% year-over-year. Patients currently access cannabis through three channels: importing with ANVISA authorization, purchasing from pharmacies (49 registered products as of early 2026), and through patient associations that are now permitted to cultivate under the new framework.
R$15 Billion Market Projection
The long-term outlook for the Brazil cannabis market 2026 and beyond is substantial. A survey by pharmaceutical company Ease Labs projects that the medicinal cannabis market in Brazil could reach R$15 billion by 2034 — roughly USD 3 billion at current exchange rates. This projection accounts for anticipated regulatory liberalization under the new ANVISA framework.
If realized, this growth would require an additional 64,000 hectares of cannabis cultivation, create an estimated 15,000 new jobs, capture 1.1 million tons of CO2 from the environment, and deliver a nearly five-fold return on investment. These projections position Brazil alongside Germany, Australia, and Thailand as a top-tier destination for cannabis investment.
ANVISA Regulatory Framework: The Four New RDCs of 2026
The centerpiece of the Brazil cannabis market 2026 story is ANVISA’s new regulatory framework. On January 28, 2026, ANVISA approved four Collegiate Board Resolutions (RDCs) that were published in the Federal Register on February 3, 2026. These rules were issued in compliance with a November 2024 ruling by Brazil’s Superior Court of Justice (IAC #16), which recognized the legality of cannabis cultivation by legal entities for medical and pharmaceutical purposes and ordered ANVISA to regulate the activity within six months.
The framework has been characterized by legal analysts as “restrictive, incremental, and intentionally conservative” — organizing the sector before expanding it and establishing limits before inviting growth. Here is what each RDC covers.
RDC #1,013/2026 — Medicinal Cultivation
This resolution regulates the cultivation of Cannabis sativa L. with THC content equal to or below 0.3%, exclusively for medicinal and research purposes. Operators must obtain a Special Authorization from ANVISA and comply with detailed requirements for control, traceability, laboratory testing, and transportation. Companies currently operating under court decisions have until August 5, 2027 to achieve full compliance.
RDC #1,012/2026 — Research Cultivation
This resolution establishes requirements for cannabis cultivation exclusively for research purposes. Only legal entities previously accredited by ANVISA may cultivate under this framework. The resolution sets stringent criteria for authorization, security, control, traceability, and storage, and expressly prohibits commercialization of research-grown cannabis.
RDC #1,014/2026 — Regulatory Sandbox
One of the most innovative elements of the Brazil cannabis market 2026 framework is the Regulatory Sandbox established by RDC #1,014. This resolution allows controlled and temporary testing of medicinal cannabis activities, supervised by ANVISA with limited regulatory flexibility. Patient associations are recognized as legitimate participants in these sandbox environments. The sandbox is designed to generate evidence that will inform future regulatory decisions — a signal that further liberalization may follow.
RDC #1,015/2026 — Sanitary Standards
This resolution establishes specific sanitary rules for all medicinal cannabis activities, reinforcing technical criteria, sanitary controls, and traceability mechanisms. For international operators, this RDC is critical because it defines the quality management and documentation standards that any participant in the Brazil cannabis market 2026 must meet.
License Types and Market Entry Requirements
For international operators considering the Brazil cannabis market 2026, understanding the license landscape is essential. The new ANVISA framework creates several distinct pathways for market participation.
Cultivation Licenses (THC <= 0.3%)
Under RDC #1,013/2026, cultivation licenses are available for cannabis plants with THC content at or below 0.3%. Applicants must:
- Be a legal entity registered in Brazil
- Obtain Special Authorization from ANVISA
- Implement full traceability from seed to finished product
- Maintain laboratory testing protocols for THC verification
- Comply with transportation security requirements
Cultivation for research purposes (under RDC #1,012) has additional restrictions, requiring prior ANVISA accreditation and prohibiting any commercial use of harvested material.
Manufacturing and Pharmaceutical Requirements
Brazil’s pharmaceutical market is highly regulated, and cannabis products must meet the same GMP (Good Manufacturing Practice) standards as conventional medicines. As of early 2026, 49 cannabis-based products hold registration with ANVISA for pharmacy distribution. Compounding pharmacies can also dispense cannabidiol-based products through individualized medical prescriptions.
Import/Export Pathways
Historically, Brazil’s medical cannabis market relied almost entirely on imports. Patients and companies obtained ANVISA authorization to import products, creating a market that was functional but inefficient. The 2026 framework is designed to reduce import dependency by enabling domestic cultivation and production. However, import pathways remain available and will continue to serve as an important channel, particularly during the transition period before domestic production scales.
Market Opportunity for International Operators and Investors
The Brazil cannabis market 2026 offers a combination of factors that make it uniquely attractive for international cannabis companies.
Why Brazil Matters: 215 Million People and Growing Demand
Brazil’s population of over 215 million makes it the fifth-largest country in the world and the largest in Latin America. The country’s healthcare infrastructure serves patients across more than 5,500 municipalities, and cannabis demand has been growing at rates that outpace most other markets globally.
Brazil, along with Mexico and Argentina, is expected to account for 12% of legal cannabis spending outside of the United States and Canada, with the broader Latin American medical cannabis market growing at a CAGR of 16.74%. The Brazil cannabis market 2026 is the anchor of this regional growth.
Economic Impact and Job Creation
The economic multiplier effects of a fully developed Brazilian cannabis industry are significant. Beyond the direct market revenue, the sector is projected to:
- Create 15,000+ direct jobs in cultivation, manufacturing, and distribution
- Require 64,000 hectares of new agricultural land dedicated to cannabis
- Capture 1.1 million tons of CO2 annually through hemp and cannabis cultivation
- Generate substantial tax revenue for federal and state governments
- Attract foreign direct investment into Brazil’s agricultural and pharmaceutical sectors
For investors, the nearly five-fold projected return on investment makes Brazil one of the highest-potential cannabis markets in the world.
Compliance Infrastructure: How GrowerIQ Supports Brazilian Market Entry
Operating in the Brazil cannabis market 2026 requires more than capital — it demands robust compliance infrastructure. ANVISA’s new RDCs place heavy emphasis on traceability, laboratory documentation, and sanitary controls. International operators entering Brazil need systems that can meet these requirements from day one.
Seed-to-Sale Tracking for ANVISA Traceability
ANVISA’s RDC #1,013 and RDC #1,015 both mandate comprehensive traceability from seed to finished product. GrowerIQ’s seed-to-sale tracking platform provides exactly this capability, offering real-time inventory management, batch tracking, and chain-of-custody documentation that aligns with ANVISA’s requirements. For operators managing cultivation under the new Brazil cannabis market 2026 framework, having a purpose-built tracking system is not optional — it is a regulatory necessity.
Digital Record-Keeping and Audit Readiness
The new framework requires detailed record-keeping for security, control, and transportation activities. GrowerIQ’s cannabis compliance software digitizes these processes, ensuring that audit trails are complete, tamper-proof, and instantly accessible. Whether your operation is applying for Special Authorization or preparing for an ANVISA inspection, digital compliance tools reduce the risk of regulatory violations that could jeopardize your license in the Brazil cannabis market 2026.
Frequently Asked Questions About the Brazil Cannabis Market 2026
Is cannabis legal in Brazil in 2026?
Medical cannabis is legal in Brazil, and the regulatory framework expanded significantly in January 2026 when ANVISA approved four new RDCs governing cultivation, research, regulatory sandboxes, and sanitary standards. Recreational cannabis remains illegal, though the Supreme Federal Court has ruled that personal possession of up to 40 grams and home cultivation of up to six plants are decriminalized.
How large is the Brazil cannabis market in 2026?
The Brazil cannabis market 2026 builds on a base of USD 856.53 million (2025 valuation) and is projected to grow to USD 1,546.74 million by 2034 at a CAGR of 6.79%. In Brazilian reais, the market could reach R$15 billion by 2034 according to Ease Labs projections.
What are ANVISA’s new cannabis regulations?
ANVISA published four new Collegiate Board Resolutions (RDCs) in February 2026: RDC #1,012 (research cultivation), RDC #1,013 (medicinal cultivation with THC <= 0.3%), RDC #1,014 (regulatory sandbox), and RDC #1,015 (sanitary standards). These take effect August 4, 2026, with a compliance deadline of August 5, 2027 for existing operators.
Can international companies operate in Brazil’s cannabis market?
Yes, but they must establish a legal entity registered in Brazil and obtain the appropriate ANVISA authorizations. The new framework creates clear pathways for cultivation, manufacturing, and research activities. International partnerships and investment are actively encouraged under the new RDCs.
What compliance tools are needed for the Brazilian cannabis market?
Operators in the Brazil cannabis market 2026 need seed-to-sale tracking systems, GMP-compliant quality management, laboratory information management, and digital record-keeping for ANVISA audits. GrowerIQ provides these capabilities through its comprehensive cannabis compliance software platform.
Sources: Agencia Brasil, Lexology / Licks Attorneys, High Times, Cannabis Industry Data, Grand View Research
Ready to Enter the Brazil Cannabis Market?
See how GrowerIQ’s compliance platform supports ANVISA requirements from day one.
REQUEST DEMO
About GrowerIQ
GrowerIQ is changing the way producers use software - transforming a regulatory requirement into a robust platform to learn, analyze, and improve performance.
To find out more about GrowerIQ and how we can help, fill out the form to the right, start a chat, or contact us.